Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [41] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS
    Uemura, H.
    Ou, Y. -C.
    Lim, H. Y.
    Tomita, Y.
    Ueda, T.
    Menon, H.
    Chung, J.
    Guo, J.
    Tarazi, J.
    Kim, S.
    Naito, S.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 6 - 6
  • [43] Axitinib for renal cell carcinoma
    Sonpavde, Guru
    Hutson, Thomas E.
    Rini, Brian I.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (05) : 741 - 748
  • [44] Experience with sorafenib in the treatment of advanced renal cell carcinoma
    Procopio, Giuseppe
    Verzoni, Elena
    Testa, Isabella
    Nicolai, Nicola
    Salvioni, Roberto
    DeBraud, Filippo
    THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (06) : 303 - 313
  • [45] Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma:a meta-analysis
    Fei Qin
    Hao Yu
    Changrong Xu
    Huihui Chen
    Jianling Bai
    TheJournalofBiomedicalResearch, 2018, 32 (01) : 30 - 38
  • [46] Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    Wilding, George
    Hudes, Gary
    Stadler, Walter M.
    Kim, Sinil
    Tarazi, Jamal
    Rosbrook, Brad
    Trask, Peter C.
    Wood, Laura
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4462 - 4468
  • [47] Pharmacogenetic AUC model can predict efficacy from neoadjuvant axitinib in advanced renal cell carcinoma
    Yamamoto, Yoshiaki
    Tsunedomi, Ryouichi
    Fujita, Yusuke
    Kawai, Yoshihisa
    Matsumoto, Hiroaki
    Hamamoto, Yoshihiko
    Hazama, Shoichi
    Nagano, Hiroaki
    Matsuyama, Hideyasu
    CANCER SCIENCE, 2018, 109 : 336 - 336
  • [48] Correlation of insulin-receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma.
    Takahashi, Masayuki
    Daizumoto, Kei
    Tsuda, Megumi
    Kusuhara, Yoshito
    Mori, Hidehisa
    Shintani, Terumichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [49] Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: Subanalyses from a phase III trial
    Escudier, B.
    Motzer, R. J.
    Lim, H. Y.
    Porfiri, E.
    Zalewski, P.
    Kannourakis, G.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S673 - S674
  • [50] Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Rini, Brian I.
    Motzer, Robert J.
    Tarazi, Jamal
    Kim, Sinil
    Huang, Xin
    Rosbrook, Brad
    English, Patricia A.
    Loomis, A. Katrina
    Williams, J. Andrew
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 328 - U239
12345